共有 1 页
品牌 | 货号 | 包装单位 | 货期 | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|
罗恩 | R026765-100mg | 100mg | 现货 |
Vc-MMAD Vc-MMAD |
99% |
|
|
罗恩 | R026765-10mg | 10mg | 现货 |
Vc-MMAD Vc-MMAD |
99% |
|
|
罗恩 | R026765-25mg | 25mg | 现货 |
Vc-MMAD Vc-MMAD |
99% |
|
|
罗恩 | R026765-50mg | 50mg | 现货 |
Vc-MMAD Vc-MMAD |
99% |
|
|
罗恩 | R026765-5mg | 5mg | 现货 |
Vc-MMAD Vc-MMAD |
99% |
|
|
阿拉丁 | V125316-5mg | 5mg | 现货 |
Vc-MMAD,用于偶联抗体 Vc-MMAD |
≥97% |
|
|
阿拉丁 | V125316-10mg | 10mg | 现货 |
Vc-MMAD,用于偶联抗体 Vc-MMAD |
≥97% |
|
|
阿拉丁 | V125316-25mg | 25mg | 现货 |
Vc-MMAD,用于偶联抗体 Vc-MMAD |
≥97% |
|
|
阿拉丁 | V125316-50mg | 50mg | 现货 |
Vc-MMAD,用于偶联抗体 Vc-MMAD |
≥97% |
|
|
阿拉丁 | V125316-100mg | 100mg | 现货 |
Vc-MMAD,用于偶联抗体 Vc-MMAD |
≥97% |
|
|
凯为 | JZ009DFN-25mg | 25mg | 期货,请咨询 |
Vc-MMAD,用于偶联抗体 VcMMAD |
98% |
|
|
毕得 | BD630225-25mg | 25mg | 现货 |
4-((S)-2-((S)-2-(6-(2,5-二氧代-... Vc-MMAD |
98% |
|
|
毕得 | BD630225-50mg | 50mg | 现货 |
4-((S)-2-((S)-2-(6-(2,5-二氧代-... Vc-MMAD |
98% |
|
|
TRC | V756600-1mg | 1mg | 4-6周 |
Vc-MMDA Vc-MMDA |
咨询 | 请联系客服购买! | |
TRC | V756600-2.5mg | 2.5mg | 4-6周 |
Vc-MMDA Vc-MMDA |
咨询 | 请联系客服购买! | |
源叶 | S83122-1mg | 1mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
源叶 | S83122-5mg | 5mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
源叶 | S83122-10mg | 10mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
Target Mol | T18870-25mg | 25mg | 现货 |
化合物Vc-MMAD Vc-MMAD |
98% |
|
|
Target Mol | T18870-50mg | 50mg | 现货 |
化合物Vc-MMAD Vc-MMAD |
98% |
|
|
Target Mol | T18870-10mg | 10mg | 现货 |
化合物Vc-MMAD Vc-MMAD |
98% |
|
|
Target Mol | T18870-1mg | 1mg | 现货 |
化合物Vc-MMAD Vc-MMAD |
98% |
|
|
Target Mol | T18870-100mg | 100mg | 现货 |
化合物Vc-MMAD Vc-MMAD |
98% |
|
|
Target Mol | T18870-5mg | 5mg | 现货 |
化合物Vc-MMAD Vc-MMAD |
98% |
|
|
Am | A371033-2mg | 2mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
Am | A371033-5mg | 5mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
Am | A371033-1mg | 1mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
Am | A371033-50mg | 50mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
Am | A371033-25mg | 25mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|
Am | A371033-10mg | 10mg | 现货 |
Vc-MMAD Vc-MMAD |
98% |
|
|